Director of Residency Training Programs/Staff Oncologist VCA Albuquerque, New Mexico, United States
Disclosure(s):
Barbara E. Kitchell, DVM, PhD, DACVIM (SAIM & Oncology: No financial relationships to disclose
Over 100 small molecular inhibitors have been licensed by the FDA for human oncology use. In veterinary medicine, and increasing number of these agents are being investigated for use in dogs and cats. Several issues must be addressed in order to use these agents successfully, including molecular target identification, in vitro evidence of activity against the target, achievable clinical dose, pharmakokinetics in the target species, and verifying the efficacy and use of compounded agents. While clinical trials have been performed or are underway, small molecular inhibitors provide a personalized approach to cancer therapy for each patient and tumor. How do we best negotiate these various issues to select the appropriate agents for optimal patient care in oncology practice?
Learning Objectives:
Upon completion, the participant will be able to assess existing literature in support of the use of specific small molecular inhibitors for individual mutations and disease indications.
Upon completion, the participant will be better able to define the pitfalls of small molecular inhibitor use in canine and feline oncology.
Upon completion, the participant will be better able to utilize individual small molecular inhibitors in clinical practice.
